Regulus Therapeutics Inc.

NASDAQ: RGLS · Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM

Regulus Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 302K 302K 302K 302K n/a n/a n/a n/a n/a n/a n/a n/a 5M 10M 10M
Cost of Revenue
259K 340K 246K 302K 260K 227K 184K 160K 144K 122K 4.5M 4.5M 4.52M 4.83M 4.37M 8.37M 12.56M
Gross Profit
81K n/a 56K n/a 42K 75K -184K -160K -144K -122K -4.5M -4.5M -4.52M -4.83M 631K 1.63M -2.56M
Operating Income
-51.75M -50.04M -44.6M -37.51M -32.57M -31.11M -29.74M -29.18M -29.04M -28.24M -28.27M -29.12M -28.59M -27.82M -21.88M -14.56M -14.42M
Interest Income
3.4M 3.84M 3.23M 2.51M 1.7M 1.68M 1.66M 1.41M 1.01M 605K 313K 127K 869K 864K 929K 966K 155K
Pretax Income
-47.52M -46.36M -41.63M -35.39M -31.37M -30.04M -28.77M -28.5M -28.74M -28.32M -28.66M -29.74M -28.51M -27.81M -21.99M -14.88M -15.8M
Net Income
-47.52M -46.36M -41.63M -35.39M -31.37M -29.99M -28.73M -28.44M -28.77M -28.39M -28.73M -29.82M -28.51M -27.81M -22M -14.89M -15.81M
Selling & General & Admin
15.59M 14.65M 13.1M 11.87M 10.28M 9.94M 9.64M 9.26M 9.38M 9.83M 10.16M 10.41M 10.43M 10.02M 9.55M 9.1M 8.87M
Research & Development
36.08M 35.3M 31.33M 25.48M 22.21M 21.1M 20.1M 19.92M 19.66M 18.41M 18.11M 18.71M 18.15M 17.79M 17.34M 15.46M 15.55M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -173K -173K -173K -388K -501K -501K -501K
Operating Expenses
51.66M 49.95M 44.43M 37.35M 32.49M 31.03M 29.74M 29.18M 29.04M 28.24M 28.27M 29.12M 28.59M 27.82M 26.88M 24.56M 24.42M
Interest Expense
59K 157K 258K 390K 500K 604K 686K 724K 718K 688K 706K 741K 795K 856K 1.03M 1.29M 1.53M
Selling & Marketing Expenses
-20K -20K -40K -40K -20K -20K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
41.47M 50.3M 44.6M 37.51M 32.57M 31.11M 29.74M 29.18M 29.04M 28.24M 28.27M 29.12M 28.59M 27.82M 26.88M 24.56M 24.42M
Income Tax Expense
1K -80K -80K -136K -136K -100K -99K -55K 27K 73K 72K 85K 3K 2K 9K 9K 18K
Shares Outstanding (Basic)
66.17M 65.5M 65.47M 64.47M 28.75M 20.22M 19.63M 19.1M 16.84M 16.84M 14.97M 14.61M 14.6M 10.69M 8.7M 7.72M 7.13M
Shares Outstanding (Diluted)
66.17M 65.5M 65.47M 64.47M 28.75M 20.22M 19.63M 19.1M 16.84M 16.84M 14.97M 14.61M 14.6M 10.69M 8.7M 7.72M 7.13M
EPS (Basic)
-0.73 -0.87 -1.07 -1.26 -1.46 -1.59 -1.59 -1.69 -1.82 -1.86 -2.13 -2.62 -2.9 -3.28 -2.89 -2.3 -3.85
EPS (Diluted)
-0.73 -0.87 -1.07 -1.26 -1.46 -1.59 -1.59 -1.69 -1.82 -1.86 -2.13 -2.62 -2.9 -3.28 -2.89 -2.3 -3.85
EBITDA
-48.08M -45.85M -41.03M -34.7M -30.61M -29.2M -27.9M -27.61M -27.88M -27.51M -27.86M -28.9M -27.61M -26.53M -20.43M -12.99M -13.59M
EBIT
-37.81M -46.2M -41.37M -35M -30.87M -29.43M -28.08M -27.77M -28.02M -27.63M -27.95M -29M -27.72M -26.95M -20.95M -13.59M -14.26M
Depreciation & Amortization
266K 347K 336K 302K 260K 227K 184K 160K 144K 122K 130K 136K 150K 459K 523K 599K 676K